about
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancerLow-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature.Participants' uptake of clinical trial results: a randomised experiment.High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterizationInternational expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentComplementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer.A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitorPathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal CancerPrognostic and predictive value of PDL1 expression in breast cancer.Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.Are there candidates for high-dose chemotherapy in ovarian carcinoma?Genomic and expression analysis of microdissected inflammatory breast cancer.Comparative genomic analysis of primary tumors and metastases in breast cancer.BetaHCG secretion by a pulmonary adenocarcinoma.Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study.Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profilingGene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survivalHeterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study.Assessment of prognostic scores in brain metastases from breast cancer.Clinical development of mTOR inhibitors in breast cancer.Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.MARCKS protein overexpression in inflammatory breast cancer.Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review.Genomic profiling of inflammatory breast cancer: a review.Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer.UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.Transparency in the presentation of trial results may not increase patients' trust in medical researchers.The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target.Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups.Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis.Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
P50
Q27853354-E2B02ABC-E3C5-415F-9EBE-91CAF28A00D3Q28483867-3298F2A2-B5F4-4BA2-AC0A-8A1165EAF520Q33755428-0F711133-824D-4B0D-B12C-9E764A57F2FCQ33783036-542DCB57-E182-4294-A744-DAFA55182418Q33826097-5226BCCC-C493-4EC5-9538-31B5F549F00EQ33870504-1001E102-1B68-4F38-90F1-A1F46B84CF76Q34339847-BD95D545-141F-4A32-B750-8215012C421FQ35017523-FE8D6418-0171-451A-A3D7-42B2ACDE95BCQ35075218-7777A57D-8FF1-4FD8-86CD-955F519EA87BQ35176131-13BCE04E-300A-4622-A16C-726EE91AB519Q35533590-A4BE10B6-A6B7-40F3-8621-E0389C06B599Q35593473-B2351ADD-B5E4-4329-BCE5-4CF33DAF97FCQ35741710-9FEDD930-3588-421E-B449-D8948659248CQ35807180-B307F635-3E5E-4B1A-8164-1AC9DDBF8BA5Q36468856-B95A13EE-3755-4197-9ACE-03B1157B489EQ36916724-C6D330A6-C7B1-4CD7-8E8E-E117493E8348Q37317214-E0B034CE-CA26-4804-81BA-B663CF615B1BQ37357369-21E52E63-5E7B-4856-A47F-2D0803100C5DQ37427956-CCFFD62E-0CF5-4DB3-AA44-3A2458BF7358Q37458486-B0B23283-C8ED-4FE8-B6E1-AA0C65884B6BQ37528475-C5C0FCB7-35CB-482A-AE00-4379766ACEE3Q37564518-209DAA39-F0BC-4BF7-A44A-2BC6A7EB9F03Q37580489-54770AA2-D0E5-4190-9AF3-0FBB49C0BEDBQ37690076-EB24E735-1427-4C55-9631-2A30E4DF98A7Q37694797-4BBC091D-7AB4-4B85-9365-12935F17A04CQ37701585-9E56F357-7A72-4A8F-B931-94D3A03CE104Q37989260-33A83AC9-3557-44C8-AF11-AACE2B9B560DQ38115153-8CB48139-C180-4227-94E0-AC930C9D27F8Q38226700-6E61EDD4-E0F3-4494-AC41-13255799AD94Q38375218-B3E3AB29-2697-4323-95A4-43C31B38F5B9Q38412031-22BDAB59-7421-43F1-B790-4D2BCE8EA316Q38481756-FA9BC2E8-7865-4495-845E-591DA7370311Q38683638-075FBE9C-2186-45A8-B409-20300178DF30Q38794688-8D24533C-6F6B-414F-9625-9775CB345012Q39346398-D85D1050-1619-4A89-BCBE-7008303017FDQ39500345-CD161E75-FBE0-4115-820E-279FAB0AE013Q39640189-27ACD938-7095-4431-9ACE-2B1B32FABFC0Q39744912-BAE91D94-218A-4DFF-9726-E8E07DBA1288Q39966200-A8E2F1D3-5DD7-45BD-80CB-39F4E7FBD897Q40035188-309639E6-A7BB-493E-9DE1-85C3B9081557
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Patrice Viens
@ast
Patrice Viens
@en
Patrice Viens
@es
Patrice Viens
@nl
type
label
Patrice Viens
@ast
Patrice Viens
@en
Patrice Viens
@es
Patrice Viens
@nl
prefLabel
Patrice Viens
@ast
Patrice Viens
@en
Patrice Viens
@es
Patrice Viens
@nl
P106
P31
P496
0000-0003-1511-1048